Assessments of relative efficacy , effectiveness , safety ( serious adverse events ) , and immunogenicity ( hemagglutination-inhibition [ HAI ] titers ) were performed during the 2011-2012 ( year 1 ) and the 2012-2013 ( year 2 ) northern-hemisphere influenza seasons .